Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quetiapine and placebo Clear all
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Trial of Quetiapine in Anorexia Nervosa

NCT00518973
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Quetiapine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Bipolar Depression

NCT00811473
View directory record Official record
Conditions
Bipolar Depression
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00081380
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
81
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Early Phase 1 Interventional

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

NCT00606541
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

NCT00579280
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
quetiapine SR, divalproex sodium ER, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171
View directory record Official record
Conditions
Delirium
Interventions
quetiapine, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

NCT00893581
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Quetiapine & Placebo, Lithium and Placebo, Healthy Controls
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

NCT00326144
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

NCT00113295
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Continued Paroxetine CR, Quetiapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Recovering Opiate Dependence

NCT00668265
View directory record Official record
Conditions
Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
Interventions
Quetiapine
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

NCT03818256
View directory record Official record
Conditions
Antipsychotic-induced Weight Gain (AIWG)
Interventions
Miricorilant, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

NCT02845453
View directory record Official record
Conditions
Substance Use Disorders, Bipolar Disorder, Mood Disorders
Interventions
Quetiapine, Placebo
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
15 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

NCT01153490
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glen Oaks, New York • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

NCT00321490
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder

NCT00320268
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
37
States / cities
Little Rock, Arkansas • Newport Beach, California • Northridge, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370
View directory record Official record
Conditions
Combat Disorders, Stress Disorders, Post-Traumatic
Interventions
Open Label (OL) Paroxetine, Placebo, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Quetiapine for Bipolar Disorder and Alcohol Dependence

NCT00457197
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Dependence
Interventions
Placebo, Quetiapine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional Results available

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

NCT00746421
View directory record Official record
Conditions
Bipolar Disorder, Cognitive Impairment
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 10, 2026, 2:55 AM EDT